



Imdusiran (AB-729) administered every 8 weeks for 24 weeks followed by the immunotherapeutic VTP-300 maintains lower HBV surface antigen levels in NA-suppressed CHB subjects than 24 weeks of imdusiran alone

<u>Kosh Agarwal</u>¹, Man-Fung Yuen², Stuart Roberts³, Gin-Ho Lo⁴, Chao-Wei Hsu⁵, Wan-Long Chuang⁶, Chi-Yi Chen⁷, Pei-Yuan Su⁸, Sam Galhenage⁹, Sheng-Shun Yang¹⁰, Emily P. Thi¹¹, Katie Anderson¹², Deana Antoniello¹³, Elina Medvedeva¹³, Timothy Eley¹³, Tilly Varughese¹³, Louise Bussey¹², Charlotte Davis¹², Antonella Vardeu¹², Christine L. Espiritu¹¹, Sharie C. Ganchua¹¹, Christina lott¹¹, Tom Evans¹², Karen D. Sims¹³

¹Institute of Liver Studies, King's College Hospital, London, United Kingdom, ²The University of Hong Kong, Queen Mary Hospital, Hong Kong, China, ³Alfred Health, Monash University, Melbourne, Australia, ⁴E-Da Hospital, Kaohsiung City, Taiwan, ⁵Chang Gung Memorial Hospital - Lin Kou, Chang Gung University College of Medicine, Taoyuan, Taiwan, ⁶Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, ⁷Chia-Yi Christian Hospital, Ditmanson Medical Foundation, Chiayi City, Taiwan, ⁸Changhua Christian Hospital, Changhua, Taiwan, ⁹Fiona Stanley Hospital, Murdoch, Australia, ¹⁰Taichung Veterans General Hospital, Taichung, Taiwan, ¹¹Arbutus Biopharma, Research, Warminster, PA, United States, ¹²Barinthus Biotherapeutics, Harwell, United Kingdom, ¹³Arbutus Biopharma, Clinical Development, Warminster, PA, United States



Disclosures – Dr. Kosh Agarwal


- Consultancy: Aligos, ASC Therapeutics, Bluejay Therapeutics, DrugFarm, Gilead, GSK, Grifols, Janssen, PrecisionBio, Roche, Surrozen, Tune, Vir
- Grants: Gilead, GSK, Abbott





Background

- Current approved therapies for chronic hepatitis B (CHB) slow or prevent the development of HBV-related liver complications, but do not typically lead to functional cure (HBV DNA suppression and HBV surface antigen [HBsAg] loss, with or without HBsAb seroconversion at least 6 months off all treatment)¹⁻³
- Excess production of HBsAg is believed to contribute to host immune exhaustion, resulting in inadequate T-cell and B-cell responses to CHB infection and failure to suppress the virus⁴
- Therapeutic success will require a combination of agents with complementary mechanisms of action to suppress HBV DNA, reduce HBsAg to low levels, and enhance HBV-specific T-cell responses



BIOPHARMA

¹European Association for the Study of the Liver. J Hepatol, 2017. 67(2):370-398.
²Sarin SK, et al. Hepatol Int, 2016. 10(1):1-98.
³Terrault N, et al. Hepatol, 2018. 67(4):1560-1599.
⁴Yuen MF, et al. Nature Reviews Disease Primers, 2018. 4:18035.




Study Rationale

- Preclinical data in the AAV-HBV mouse model supports lowering HBsAg with an siRNA then following with a therapeutic vaccine to potentiate HBsAg loss and T cell responses¹
- Imdusiran for 24 weeks (to reduce HBsAg to low levels), followed by VTP-300 (to enhance HBV-specific T cell responses) in NA-suppressed CHB patients may promote HBsAg loss which may lead to functional cure
- Imdusiran (AB-729/IDR)²⁻⁴
 - GalNAc-conjugated, single trigger siRNA that blocks all HBV RNA transcripts (including HBx), suppressing viral replication and production of all viral antigens
 - Subcutaneously administered, 60 mg every 8 weeks
 - Lowers mean HBsAg levels by $\sim 1.5 2 \log_{10}$ after 24 48 weeks of treatment in combination with NA in multiple studies

• VTP-300 immunotherapeutic⁵⁻⁷


- 2 viral vectors encoding the same consensus HBV viral sequences used in sequential combination:
 - Chimpanzee adenoviral vector (ChAdOx1-HBV)
 - Modified Vaccinia Ankara vector (MVA-HBV)
- Generates robust T-cell responses and induces sustained HBsAg declines in a subset of subjects with low HBsAg (<200 IU/mL)
- Maximal effects on HBsAg reduction observed at least 3 months after dosing



¹Michler, T. et al. Gastroenterology 2020; 158:1762-1775
 ²Yuen, MF et al. Journal of Hepatology 2022, Volume 77, S876 - S877
 ³Yuen, MF et al. 2024 EASL Congress Poster WED-371
 ⁴MacQuillan, G et al. Hepatology 78(S1):p S1-S2154
 ⁵Evans, T et al. Journal of Hepatology 2023, Volume 78, S1169 - S1170
 ⁶Sorensen, H et al. Hepatology 2023 78(S1):p S1-S2154
 ⁷Tak WY et al. Journal of Hepatology 2024, accepted manuscript **CARINTHUS**

Study overview: IM-PROVE II (AB-729-202)

- IM-PROVE II is a randomized, placebo-controlled, multicenter Phase 2a proof-of-concept study (ACTRN12622000317796)
- Primary Objective: To evaluate the safety and reactogenicity of the combination of imdusiran followed by VTP-300 or placebo injection
- Week 48/EOT data is reported for 38/40 subjects who reached timepoint, data to Week 72 and beyond reported as available*



Study population:

- NA-suppressed for at least 12 months with HBV DNA < 20 IU/mL
- HBeAg-positive or -negative
- HBsAg \geq 100 IU/mL and < 5000 IU/mL
- ALT $\leq 2 \times ULN$
- Non-cirrhotic

BIOPHARMA

Protocol decision rules:

- Optional 2nd MVA-HBV boost/placebo dose at Week 38:
 - Additional $\geq 0.5 \log_{10}$ HBsAg decline between Weeks 26 and 34
- NA discontinuation occurred after Week 48/EOT visit if all criteria were met:
 - HBV DNA < LLOQ
 - HBeAg negative

• HBsAg < 100 IU/mL

ALT <2 × ULN



*Data cut date April 12, 2024 5

Demographics: Baseline characteristics were comparable between groups

- Median baseline HBsAg was over 800 IU/mL in each Group
- Mostly male, Asian, with HBV genotype B or C
- More HBeAg+ subjects were randomized to Group
 B/placebo (not stratified)

Assay methods:

Parameter	Assay Method	Lower Limit of Quantitation	Imputed values for results <lloq< th=""></lloq<>
HBsAg	Diasorin Liaison XL	0.05 IU/mL	0.035 IU/mL
HBV DNA	Cepheid GeneXpert	10 IU/mL	<lloq 5,="" =="" tnd="1</td"></lloq>
HBeAg	Diasorin Liaison XL	0.09 PEI U/mL	0.055 PEI U/mL
HBsAb	Siemens Centaur	10 mIU/mL	3.1 mIU/mL
HBV pgRNA	Abbott HBV pgRNA V2.0 (RUO)	0.49 log U/mL	0.48 log U/mL
HBcrAg	Fujirebio Lumipulse G	3 log U/mL	1.45 log U/mL
HBV GT	DNA/RNA Sequencing	Not amplifiable	N/A

Parameter	Group A VTP-300 (N=20)	Group B Placebo (N=20)	Total (N=40)
Age, mean (SD)	52.2 (6.45)	44.3 (8.33)	48.2 (8.37)
Males, n (%)	14 (70)	14 (70)	28 (70.0)
Race Asian White Black/African American	18 (90) 1 (5) 1 (5)	19 (95) 1 (5) 0	37 (92.5) 2 (5.0) 1 (2.5)
HBV Genotype, n (%) B C D Not detected*	5 (25) 7 (35) 1 (5) 7 (35)	7 (35) 7 (35) 0 6 (30)	12 (30) 14 (35) 1 (2.5) 13 (32.5)
HBsAg, IU/mL Median Mean Range	820 1123 95 - 4000	870 1135 100 – 3300	820 1129 95 - 4000
Baseline ALT mean (SD), U/L	20.7 (9.50)	22.1 (11.12)	21.7 (10.23)
HBeAg Positive, n (%) Median (range) (PEI U/mL)	4 (20) 0.19 (0.1 – 89.3)	10 (50) 0.31 (0.1 – 93.1)	14 (35) 0.31 (0.1 – 93.1)

*Subjects were NA suppressed at baseline, thus not all had amplifiable DNA or RNA for sequencing





Safety: The combination of imdusiran and VTP-300 was well-tolerated


Subjects, N (%) [Events]	Imdusiran Lead-in (N=40)	Group A VTP-300 (N=20)	Group B Placebo (N=20)	Study Total (N=40)
Any TEAE Grade 1 Grade 2 Grade 3 Grade 4	22 (55%) [44] 19 (47.5%) [40] 2 (5.0%) [2] 0 0	12 (60%) [22] 7 (36.8%) [16] 3 (15.8%) [4] 0 0	12 (60%) [24] 5 (27.8%) [12] 1 (5.6%) [2] 0 0	30 (75%) [90] 22 (55.0%) [68] 6 (15.0%) [8] 0 0
Treatment-related TEAEs Imdusiran VTP-300	4 (10%) [8] N/A	1 (5%) [1] 4 (20%) [6]	0 N/A	5 (12.5%) [9] 4 (10%) [6]
SAEs	0	0	0	0
Treatment discontinuation	0	0	0	0

TEAE: treatment-emergent adverse event; SAE: serious adverse event

- Most common treatment-related TEAEs in 2 or more subjects (all Grade 1 or 2):
 - Imdusiran: injection site-related (bruising and/or swelling in 2 subjects), ALT increased in 2 subjects
 - VTP-300: injection site-related (redness, pain and/or injection reaction in 2 subjects)
- Only 3 Grade 3 or 4 laboratory abnormalities were observed, none assessed as AEs:
 - Isolated, transient creatine kinase (CK), glucose, and INR elevations in 3 different subjects
- Well-tolerated profiles of imdusiran and VTP-300 were maintained when administered sequentially



Results: Lower HBsAg levels maintained over time in VTP-300 group




- Imdusiran led to declines of -1.8 log₁₀ by Week 26, 95% of subjects had HBsAg <100 at time of VTP-300 or placebo dosing</p>
- More subjects maintained HBsAg thresholds of <100 IU/mL and <10 IU/mL when administered VTP-300 vs placebo

BIOPHARMA

At 24 weeks post-EOT (Week 72, N=11), there was a significant difference in HBsAg levels between groups, which may reflect the delayed effect of VTP-300 on HBsAg levels observed in other trials

BARINTHUS

Results: Individual Subject HBsAg Declines by Treatment Group




• More subjects in Group A/VTP-300 have maintained low HBsAg levels at and after end of treatment

BIOPHARMA

- 1 Group A/VTP-300 subject off NA therapy [*] reached HBsAg <LLOQ at Week 72 after >2 log₁₀ decline between Week 64 and 72, another subject off NA therapy [#] has had >1.5 log₁₀ decline in HBsAg between Week 60 and 68
- 1 subject in Group B/placebo has had continuous HBsAg <LLOQ for > 6 months (remained on NA therapy due to positive HBeAg status at Week 48)



Results: More subjects in Group A/VTP-300 stopped NA treatment



- More subjects in Group A/VTP-300 met NA discontinuation criteria and stopped treatment
 - More Group A/VTP-300 subjects (50%) have maintained HBV DNA <LLOQ off NA therapy than placebo subjects (37.5%)
 - Group A/VTP-300 subjects have maintained lower HBsAg levels after NA discontinuation
 - 1 Group A/VTP-300 subject reached HBsAg <LLOQ at Week 72, another has >1.5 log₁₀ HBsAg decline between Week 60 and 68
- NA discontinuation was well-tolerated with frequent follow-up visits and testing of HBV DNA and clinical safety labs
 - Maximal ALT of 80 U/L prior to NA restart amongst 4 subjects who restarted treatment
 - 1 subject had isolated, transient ALT of 156 U/mL after single HBV DNA elevation that spontaneously resolved without re-treatment, subsequently led to HBsAg <LLOQ



BARINTHUS

Conclusions


- Imdusiran 60 mg every 8 weeks for 24 weeks followed by VTP-300 or placebo was well-tolerated
- The combination of imdusiran and VTP-300 led to maintenance of lower HBsAg levels during the post-treatment follow-up period
- Nucleos(t)ide analogue discontinuation was achieved in the majority of subjects, with more meeting the discontinuation criteria in the VTP-300 group (84%) vs placebo (53%)
 - More subjects in the VTP-300 group have maintained HBV DNA < LLOQ and lower HBsAg levels off NA treatment vs placebo
 - NA discontinuation was well-tolerated, including in the 4 subjects who restarted NA therapy due to HBV DNA increases
 - No concerning ALT elevations were observed in those subjects
- Two VTP-300 subjects have had significant (>1.5 log₁₀) HBsAg declines in the early NA discontinuation follow-up period with one subject reaching HBsAg <LLOQ, suggesting a delayed effect of VTP-300 on HBsAg levels as has been previously observed</p>





Additional imdusiran and VTP-300 data:

- Please see Abstract #2823 (Poster WED-375): Yuen, MF et al., VTP-300 immunotherapeutic, plus low dose PD-1 inhibitor, nivolumab, continues to show meaningful, sustained reductions in HBsAg levels
- The IM-PROVE II (AB-729-202) low dose nivolumab arm (Group C) is fully enrolled, end of treatment data is expected 2H2024







Acknowledgements

Arbutus Biopharma and Barinthus Biotherapeutics thank all participating subjects and their families, the Investigators and site staff, Novotech CRO, Eurofins, Maksym Chernyakhovskyy (Arbutus) and Crystal Grant (Arbutus) for data management assistance, Deepa Patel (Arbutus) and Dereck Tait (Barinthus) for study support, and the imdusiran and VTP-300 Research and Development Teams.

Participating Sites:

UK:

• Kosh Agarwal, King's College Hospital, London

Hong Kong:

• Man-Fung Yuen, The University of Hong Kong, Queen Mary Hospital

Australia:

- Stuart Roberts, Alfred Health, Monash University, Melbourne
- Sam Galhenage, Fiona Stanley Hospital, Murdoch

Taiwan:

- Wan-Long Chuang, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung
- Gin-Ho Lo, E-Da Hospital, Kaohsiung City
- Chao-Wei Hsu, Chang Gung Memorial Hospital Lin Kou, Chang Gung University College of Medicine, Taoyuan
- Chi-Yi Chen, Chia-Yi Christian Hospital, Ditmanson Medical Foundation, Chiayi City
- Pei-Yuan Su, Changhua Christian Hospital, Changhua, Taiwan
- Sheng-Shun Yang, Taichung Veterans General Hospital, Taichung



